Rate My Professor Brian Tsuji

Tsuji's research focuses on antimicrobial pharmacodynamics, investigating resistance mechanisms in multi-drug resistant Gram-negative bacteria known as superbugs, and pharmacokinetic/pharmacodynamic modeling of antimicrobials to prevent resistance emergence through novel hollow fiber infection models and bacterial genetic analysis. As principal investigator, he has secured multiple National Institutes of Health R01 grants, including a $3.92 million award representing the second largest in the school's history, to study novel antibiotic combinations against antibiotic-resistant pathogens. He is lead author of the International Polymyxin Dosing Guidelines providing global clinical guidance on last-resort antibiotics. With over 100 peer-reviewed manuscripts, key publications include 'International consensus guidelines for the optimal use of the polymyxins' (2019), 'Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing' (2010), 'Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus' (2015), and 'Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?' (2016). His laboratory has pioneered PK/PD relationships guiding antibiotic dose selection in Phase 1, 2, and 3 clinical trials, contributing to drug approvals and defining clinical applications. Tsuji received the 2020 SUNY Chancellor's Award for Excellence in Scholarship and Creative Activities and is a Fellow of the American College of Clinical Pharmacy (FCCP), Infectious Diseases Society of America (FIDSA), and Society of Critical Care Medicine (FCCM), as well as Past-President of the International Society of Antimicrobial Pharmacology.